Female patients are less satisfied with biological treatment for psoriasis and experience more side effects than male patients. Results from the prospective BioCAPTURE registry

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Psoriasis

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T

doi: 10.1111/jdv.16632.

Psoriasis

Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: Results from a prospective, randomized, observer-blinded head-to-head trial

J Eur Acad Dermatol Venereol.

Holzer G, Hoke M, Sabeti-Sandor S, Perkmann T, Rauscher A, Strassegger B, Radakovic S, Tanew A

doi: 10.1111/jdv.16635.

Psoriasis

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Am J Clin Dermatol.

Singh S, Kalb RE, de Jong EMGJ, Shear NH, Lebwohl M, Langholff W, Hopkins L, Srivastava B, Armstrong AW

doi: 10.1007/s40257-

Further Publications Dermatology

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

J Eur Acad Dermatol Venereol

da Silva N, Sommer R, Ortmann CE, Jagiello P, Bachhuber T, Augustin M

doi: 10.1111/jdv.17525

Psoriasis

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

J Eur Acad Dermatol Venereol.

Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie

doi: 10.1111/jdv.15579.

COMMENTED

Psoriasis

Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice

J Eur Acad Dermatol Venereol.

Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French LE, Radtke MA, Augustin M

doi: 10.1111/jdv.15324.

Psoriasis

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Eur J Dermatol

Offidani A, Radi G, Bianchi L, Cannavò SP, Conti A, Gesuita R, Salaffi F, Talamonti M, Campanati A

doi: 10.1684/ejd.2021.4121

Related content

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: Results from a prospective, randomized, observer-blinded head-to-head trial

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics